Bevacizumab: the phoenix of breast oncology?
Mené au Royaume-Uni sur 800 patientes atteintes d'un cancer du sein HER2- de stade précoce, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la réponse pathologique complète, et la toxicité de l'ajout du bévacizumab à une chimiothérapie néoadjuvante de référence
Bevacizumab is a monoclonal antibody that inhibits tumour neoangiogenesis mediated by VEGF. In a meta-analysis that included 2447 patients with breast cancer treated in a first-line setting, bevacizumab slightly improved progression-free survival (HR 0·64, 95% CI 0·57–0·71; median 9·2 months vs 6·7 months) and did not improve overall survival (HR 0·97, 95% CI 0·86–1·08; 26·7 months vs 26·4 months). Guidelines recommend this drug as an option only in selected cases because of the slight improvement in progression-free survival, lack of benefit in overall survival, high cost, lack of predictive biomarkers, and associated toxicities.
The Lancet Oncology , commentaire en libre accès, 2014